Amvuttra – Talk Bio

Actionable Insights Powered by AI

Alnylam Surpasses $50B Market Cap as Amvuttra Heart Disease Launch Impresses Wall Street

1 month ago talkbio0Tagged Alnylam, Amvuttra, ATTR-CM, Caps, earnings, Heart Diseases, Market, revenue growth, Stock Surge

Alnylam Pharmaceuticals; market cap; Amvuttra; heart disease; ATTR-CM; stock surge; Q2 2025 earnings; revenue growth

Alnylam’s Amvuttra Approved for ATTR Cardiomyopathy, Challenging Pfizer and BridgeBio

6 months ago talkbio0Tagged Amvuttra, Approved, ATTR-CM, Cardiomyopathies, RNA Interference, United States Food and Drug Administration

Amvuttra, vutrisiran, ATTR-CM, FDA approval, RNAi therapeutic, cardiomyopathy